Lamictal in the Treatment of Post-Herpetic Neuralgia

George Washington University (GW)

Status and phase: Terminated; Phase 3; Phase 2

Conditions: Neuralgia, Postherpetic

Treatments: Drug: Lamictal in the treatment of Post-Herpetic Neuralgia

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00295776

Lamictal PHN

Details and patient eligibility

About

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients will be over the age of 18,
• Need to have a diagnosis of Post-Herpetic Neuralgia,
• Minimum of 4 on the Likert Pain Scale,
• If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks

Exclusion criteria

• Currently on any antiepileptic drugs (AED), except for Gabapentin.
• Currently taking opioid or unwilling to washout prior to the study,
• Pregnant and lactating,
• Have active severe systemic disease,
• History of Stevens-Johnson syndrome or TEN,
• Clinically significant abnormal lab values,
• Known drug allergy to Lamictal,
• Patients on Fibrates (Tricor and Lopid),
• History of major psychiatric disturbance and substance abuse.
• Valproate due to increase chances of severe rash,
• Lidocaine Patch,
• Use of hormonal contraceptives (birth control pills, patch, ring, injection)